These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Author: Pula JH, Javed A.
    Journal: Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177.
    Abstract:
    PURPOSE OF REVIEW: This update includes topics relating to the treatment of multiple sclerosis (MS) for the ophthalmologist. RECENT FINDINGS: Despite investigation into numerous genetic and environmental factors, the cause of MS remains elusive. MS is a disease of the central nervous system that mainly affects young people and usually progresses over time, leading to disability in multiple areas, including mobility, cognition, affect and vision. It is likely that, as novel MS treatments are introduced, there will be a greater interest in tracking visual function and monitoring for visual complications. SUMMARY: Current therapies in MS include interferon, glatiramer, natalizumab and mitoxantrone. Other MS treatments are imminent, and include oral medications, monoclonal antibodies and chemotherapy. Treatment of the visual symptoms in MS and the side effects of MS therapies are reviewed in this article.
    [Abstract] [Full Text] [Related] [New Search]